Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 8 | 2025 | 314 | 0.830 |
Why?
|
| Fragile X Syndrome | 3 | 2024 | 140 | 0.700 |
Why?
|
| Intracranial Aneurysm | 3 | 2014 | 19 | 0.590 |
Why?
|
| Aneurysm, Ruptured | 2 | 2014 | 12 | 0.520 |
Why?
|
| Postural Balance | 3 | 2025 | 62 | 0.450 |
Why?
|
| Female | 26 | 2025 | 6974 | 0.440 |
Why?
|
| Male | 25 | 2025 | 6815 | 0.440 |
Why?
|
| Deep Brain Stimulation | 3 | 2022 | 15 | 0.440 |
Why?
|
| Self-Help Groups | 1 | 2014 | 6 | 0.430 |
Why?
|
| Cholesterol | 1 | 2014 | 30 | 0.430 |
Why?
|
| Social Media | 1 | 2014 | 32 | 0.410 |
Why?
|
| Humans | 30 | 2025 | 12240 | 0.390 |
Why?
|
| Huntington Disease | 2 | 2025 | 29 | 0.380 |
Why?
|
| Middle Aged | 18 | 2025 | 4043 | 0.380 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 423 | 0.370 |
Why?
|
| Ataxia | 2 | 2024 | 51 | 0.350 |
Why?
|
| Tremor | 2 | 2024 | 60 | 0.340 |
Why?
|
| Aged | 18 | 2025 | 4000 | 0.330 |
Why?
|
| Adult | 13 | 2025 | 3557 | 0.330 |
Why?
|
| Subarachnoid Hemorrhage | 3 | 2015 | 28 | 0.300 |
Why?
|
| Psychomotor Performance | 2 | 2025 | 85 | 0.260 |
Why?
|
| Parietal Lobe | 1 | 2025 | 11 | 0.230 |
Why?
|
| Cerebral Cortex | 1 | 2025 | 77 | 0.220 |
Why?
|
| Prefrontal Cortex | 1 | 2025 | 66 | 0.220 |
Why?
|
| Health Status Disparities | 1 | 2025 | 30 | 0.220 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 34 | 0.220 |
Why?
|
| Hospital Mortality | 2 | 2015 | 72 | 0.210 |
Why?
|
| Subthalamic Nucleus | 2 | 2022 | 7 | 0.210 |
Why?
|
| Cerebral Hemorrhage | 2 | 2022 | 37 | 0.210 |
Why?
|
| Hospitalization | 2 | 2017 | 158 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2022 | 156 | 0.190 |
Why?
|
| Trinucleotide Repeat Expansion | 2 | 2014 | 27 | 0.190 |
Why?
|
| Physical Therapists | 1 | 2022 | 3 | 0.180 |
Why?
|
| Arterial Pressure | 1 | 2022 | 5 | 0.180 |
Why?
|
| Blood Pressure Determination | 1 | 2022 | 8 | 0.180 |
Why?
|
| Fragile X Mental Retardation Protein | 2 | 2014 | 82 | 0.180 |
Why?
|
| Glucosylceramidase | 1 | 2022 | 3 | 0.180 |
Why?
|
| Heterozygote | 1 | 2022 | 72 | 0.170 |
Why?
|
| Gait | 2 | 2020 | 195 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2021 | 35 | 0.160 |
Why?
|
| Young Adult | 4 | 2020 | 863 | 0.160 |
Why?
|
| Walking Speed | 1 | 2020 | 13 | 0.160 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.160 |
Why?
|
| Nootropic Agents | 1 | 2020 | 7 | 0.160 |
Why?
|
| Cognition | 2 | 2022 | 641 | 0.150 |
Why?
|
| Accidental Falls | 1 | 2020 | 39 | 0.150 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2020 | 67 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2025 | 817 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2020 | 1467 | 0.140 |
Why?
|
| Microelectrodes | 1 | 2018 | 17 | 0.140 |
Why?
|
| Electrodes, Implanted | 1 | 2018 | 8 | 0.140 |
Why?
|
| Child, Preschool | 2 | 2020 | 320 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 2152 | 0.130 |
Why?
|
| Length of Stay | 1 | 2018 | 126 | 0.130 |
Why?
|
| Diskectomy | 1 | 2018 | 65 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2017 | 6 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2017 | 11 | 0.130 |
Why?
|
| Brain | 2 | 2021 | 707 | 0.130 |
Why?
|
| Antidepressive Agents | 1 | 2017 | 48 | 0.130 |
Why?
|
| Thrombectomy | 1 | 2017 | 19 | 0.130 |
Why?
|
| Seizures | 1 | 2017 | 35 | 0.130 |
Why?
|
| Epilepsy | 1 | 2017 | 36 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 60 | 0.120 |
Why?
|
| Cervical Vertebrae | 1 | 2018 | 122 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2017 | 90 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 84 | 0.120 |
Why?
|
| Substantia Nigra | 1 | 2016 | 68 | 0.120 |
Why?
|
| alpha-Synuclein | 1 | 2016 | 59 | 0.120 |
Why?
|
| Stroke | 1 | 2017 | 117 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2018 | 385 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2018 | 176 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 18 | 0.110 |
Why?
|
| Psychometrics | 1 | 2014 | 95 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2022 | 214 | 0.100 |
Why?
|
| Risk Factors | 2 | 2014 | 1049 | 0.100 |
Why?
|
| Vascular Access Devices | 1 | 2013 | 2 | 0.100 |
Why?
|
| Hematoma, Subdural | 1 | 2013 | 4 | 0.100 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2013 | 4 | 0.100 |
Why?
|
| Cerebral Angiography | 1 | 2013 | 15 | 0.100 |
Why?
|
| Cerebral Arteries | 1 | 2013 | 18 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 38 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2020 | 256 | 0.100 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 60 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 546 | 0.090 |
Why?
|
| Ischemic Attack, Transient | 1 | 2011 | 4 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2011 | 36 | 0.090 |
Why?
|
| Cholecystokinin | 1 | 2011 | 5 | 0.080 |
Why?
|
| Circle of Willis | 1 | 2011 | 1 | 0.080 |
Why?
|
| Communication Disorders | 1 | 2011 | 2 | 0.080 |
Why?
|
| Hallucinations | 1 | 2011 | 19 | 0.080 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 2 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 7 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 110 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 122 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 182 | 0.080 |
Why?
|
| Walk Test | 2 | 2020 | 7 | 0.080 |
Why?
|
| Neuropsychological Tests | 2 | 2022 | 558 | 0.070 |
Why?
|
| Cognitive Dysfunction | 1 | 2014 | 449 | 0.070 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 800 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2011 | 437 | 0.070 |
Why?
|
| Time Factors | 2 | 2020 | 695 | 0.060 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2025 | 6 | 0.060 |
Why?
|
| False Positive Reactions | 2 | 2017 | 23 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 14 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 218 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 281 | 0.050 |
Why?
|
| Phenotype | 1 | 2025 | 157 | 0.050 |
Why?
|
| Prodromal Symptoms | 1 | 2024 | 11 | 0.050 |
Why?
|
| Disability Evaluation | 2 | 2017 | 105 | 0.050 |
Why?
|
| Adolescent | 2 | 2020 | 989 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2020 | 1478 | 0.050 |
Why?
|
| Age Factors | 2 | 2017 | 350 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2014 | 29 | 0.050 |
Why?
|
| Quality of Life | 1 | 2025 | 261 | 0.050 |
Why?
|
| Biomarkers | 1 | 2024 | 294 | 0.050 |
Why?
|
| Prevalence | 2 | 2013 | 175 | 0.050 |
Why?
|
| Radial Artery | 1 | 2022 | 6 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 113 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 62 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2022 | 99 | 0.040 |
Why?
|
| United States | 1 | 2025 | 989 | 0.040 |
Why?
|
| Radiography | 2 | 2013 | 258 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 175 | 0.040 |
Why?
|
| Logistic Models | 2 | 2012 | 196 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 36 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 3 | 0.040 |
Why?
|
| Foot | 1 | 2020 | 17 | 0.040 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 10 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 103 | 0.040 |
Why?
|
| Motor Activity | 1 | 2020 | 175 | 0.030 |
Why?
|
| Child | 1 | 2020 | 614 | 0.030 |
Why?
|
| Cameroon | 1 | 2017 | 1 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 2 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 33 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 16 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 24 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 141 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 88 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 130 | 0.030 |
Why?
|
| Locus Coeruleus | 1 | 2016 | 6 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 56 | 0.030 |
Why?
|
| Olfactory Bulb | 1 | 2016 | 7 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 166 | 0.030 |
Why?
|
| HIV Infections | 1 | 2017 | 256 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2013 | 7 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 13 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 7 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 26 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2013 | 47 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 295 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 209 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 363 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 400 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 453 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 6 | 0.020 |
Why?
|
| Models, Economic | 1 | 2011 | 6 | 0.020 |
Why?
|
| Decision Trees | 1 | 2011 | 7 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 24 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2011 | 17 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 46 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 827 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 84 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 32 | 0.020 |
Why?
|
| Hypertension | 1 | 2012 | 85 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 33 | 0.020 |
Why?
|
| Social Behavior Disorders | 1 | 2011 | 2 | 0.020 |
Why?
|
| Language Disorders | 1 | 2011 | 6 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 45 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 115 | 0.020 |
Why?
|
| Alleles | 1 | 2011 | 119 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 60 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 169 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 229 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 651 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 726 | 0.020 |
Why?
|